<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136267">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02028780</url>
  </required_header>
  <id_info>
    <org_study_id>1321.5</org_study_id>
    <nct_id>NCT02028780</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 Administered Alone or With Dabigatran Etexilate in Japanese Healthy Subjects</brief_title>
  <official_title>Randomised, Double-blind Within Dose Groups, Placebo-controlled Phase I Trial in Healthy Japanese Male Volunteers to Investigate Safety, Tolerability and Pharmacokinetics of Different Doses of BI 655075 (Part 1) and to Explore the Effective Dose of BI 655075 to Reverse Dabigatran Anticoagulant Activity (Part 2).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to investigate the safety, tolerability and pharmacokinetics of BI
      655075 following intravenous administration of single rising doses of BI 655075 when
      administered alone and after administration of dabigatran.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The number (%) of subjects with drug-related adverse events in Part 1 and Part 2</measure>
    <time_frame>up to 108 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>sum dabigatran: Ae0-72 in Part 2</measure>
    <time_frame>from Day 4 to Day 7</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sum dabigatran: Ae0-72 in Part 2</measure>
    <time_frame>from Day 11 to Day 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>unbound sum dabigatran: AUC2-12 (area under the concentration-time curve of the analyte in plasma over the time interval from 2 hour - 72 hour) in Part 2</measure>
    <time_frame>from Day 4 to Day 7</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>unbound sum dabigatran: AUC2-12 in Part 2</measure>
    <time_frame>from Day 11 to Day 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dTT (diluted thrombin time): AUEC2-12 in Part 2</measure>
    <time_frame>from Day 4 to Day 7</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dTT: AUEC2-12 in Part 2</measure>
    <time_frame>from Day 11 to Day 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BI 655075: Cmax (maximum measured concentration of the analyte in plasma) in Part 1 and Part 2</measure>
    <time_frame>up to 14 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BI 655075: AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) in Part 1 and Part 2</measure>
    <time_frame>up to 14 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BI 655075: Ae0-72 (amount of the analyte excreted in urine over the time interval from 0 to 72 hour) in Part 1 and Part 2</measure>
    <time_frame>up to 14 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 655075 single doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>different infusion durations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 655075 with dabigatran</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>short infusion with 2 capsules dabigatran</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655075</intervention_name>
    <description>short infusion</description>
    <arm_group_label>BI 655075 with dabigatran</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to dose</intervention_name>
    <description>placebo</description>
    <arm_group_label>BI 655075 single doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to BI 655075</intervention_name>
    <description>Placebo to BI 655075</description>
    <arm_group_label>BI 655075 with dabigatran</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran</intervention_name>
    <description>2 capsules dabigatran</description>
    <arm_group_label>BI 655075 with dabigatran</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655075</intervention_name>
    <description>different infusion durations</description>
    <arm_group_label>BI 655075 single doses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        1. Healthy Japanese male subjects

        Exclusion criteria:

        1. Any relevant deviation from healthy conditions
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1321.5.00001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sumida-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>January 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
